BenevolentAI Logo

BenevolentAI

An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.

BAI | AS

Overview

Corporate Details

ISIN(s):
LU2355630455
LEI:
2221003P54KEDC3P4Z33
Country:
United Kingdom
Address:
4-8 Maple Street, W1T 5HD London
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BenevolentAI is a drug discovery company specializing in the development and application of artificial intelligence for scientific innovation. The company's platform provides life science intelligence to scientists and pharmaceutical executives, leveraging a proprietary knowledge graph and machine learning models to analyze complex biomedical data. Its core mission is to accelerate the research and development process by identifying novel drug targets and understanding disease mechanisms. The technology aims to lower costs, decrease failure rates, and increase the speed of bringing new medicines to market. BenevolentAI collaborates with pharmaceutical partners and develops its own in-house drug portfolio.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-12 12:12
Delisting Announcement
BAI EGM Results APPROVED
English 169.9 KB
2025-02-06 07:00
Delisting Announcement
Merger-Delisting and Notice of EGM FINAL APPROVED copy
English 95.2 KB
2024-12-11 13:17
Delisting Announcement
BenevolentAI unveils major strategic overhaul with return to original mission
English 440.5 KB
2024-12-11 07:00
Delisting Announcement
241211_BenevolentAI Statement_FINAL
English 440.5 KB
2024-12-03 13:36
Share Issue/Capital Change
Regulatory Announcement - Issue of Equity and TVR (RSU Settlement) 03122024
English 111.3 KB
2024-10-17 07:00
Board/Management Information
241017 BenevolentAI_Leadership update_Final
English 384.6 KB
2024-09-23 14:15
Major Shareholding Notification
Major Shareholding Notification (LINK) - 13 September 2024 rev
English 494.2 KB
2024-09-19 07:00
Interim Report
240919_BAI Interims 24 press release_FINAL
English 468.9 KB
2024-07-30 12:56
Director's Dealing
PDMR Notification - Dr. Joerg Moeller
English 56.6 KB
2024-07-03 07:00
Board/Management Information
BAI_LEADERSHIP TEAM CHANGE_FINAL_03.07.2024
English 140.6 KB
2024-05-02 15:30
Post-Annual General Meeting Information
AGM Results 2 May 2024 FINAL
English 129.2 KB
2024-05-01 12:37
Major Shareholding Notification
Major Holdings Notification (Annex A) ABG-ODY-BAI LIMITED
English 62.7 KB
2024-04-23 07:00
Regulatory News Service
Business Update 23 April 24 FINAL
English 166.2 KB
2024-04-17 07:00
Pre-Annual General Meeting Information
BAI_Publication of the Revised Agenda for the 2024 AGM_FINAL_17.04.24
English 69.7 KB
2024-04-15 07:00
Board/Management Information
BAI_PROPOSED CHANGES TO BOARD COMPOSITION _FINAL_15.04.24
English 168.4 KB

Automate Your Workflow. Get a real-time feed of all BenevolentAI filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BenevolentAI via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland OCS
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea 244460
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea 382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea 476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan 4564
Onxeo Logo
Developing precision-guided therapeutics using small antibodies for complex diseases.
France ALONX
Openedges Technology, Inc. Logo
Semiconductor IP provider of memory subsystem & AI platform IP for AI, HPC, and IoT SoCs.
South Korea 394280
Openjobmetis Logo
Employment agency providing staffing, recruitment, and HR services to companies and job seekers.
Italy OJM
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154

Talk to a Data Expert

Have a question? We'll get back to you promptly.